These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
386 related articles for article (PubMed ID: 26964667)
1. Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence. Chen W; Xiao W; Zhang K; Yin X; Lai J; Liang L; Chen D Sci Rep; 2016 Mar; 6():22976. PubMed ID: 26964667 [TBL] [Abstract][Full Text] [Related]
2. Overexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell lines. Haga Y; Kanda T; Nakamura M; Nakamoto S; Sasaki R; Takahashi K; Wu S; Yokosuka O PLoS One; 2017; 12(3):e0174153. PubMed ID: 28323861 [TBL] [Abstract][Full Text] [Related]
3. In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3-Mediated Apoptosis. Fornari F; Pollutri D; Patrizi C; La Bella T; Marinelli S; Casadei Gardini A; Marisi G; Baron Toaldo M; Baglioni M; Salvatore V; Callegari E; Baldassarre M; Galassi M; Giovannini C; Cescon M; Ravaioli M; Negrini M; Bolondi L; Gramantieri L Clin Cancer Res; 2017 Jul; 23(14):3953-3965. PubMed ID: 28096271 [No Abstract] [Full Text] [Related]
4. Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1. Zhai JM; Yin XY; Lai YR; Hou X; Cai JP; Hao XY; Liang LJ; Zhang LJ Cancer Chemother Pharmacol; 2013 May; 71(5):1255-64. PubMed ID: 23435877 [TBL] [Abstract][Full Text] [Related]
5. Activation of AMP-activated protein kinase by retinoic acid sensitizes hepatocellular carcinoma cells to apoptosis induced by sorafenib. Ishijima N; Kanki K; Shimizu H; Shiota G Cancer Sci; 2015 May; 106(5):567-75. PubMed ID: 25683251 [TBL] [Abstract][Full Text] [Related]
6. Melatonin promotes sorafenib-induced apoptosis through synergistic activation of JNK/c-jun pathway in human hepatocellular carcinoma. Lin S; Hoffmann K; Gao C; Petrulionis M; Herr I; Schemmer P J Pineal Res; 2017 Apr; 62(3):. PubMed ID: 28178378 [TBL] [Abstract][Full Text] [Related]
7. Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma. Liu J; Liu Y; Meng L; Liu K; Ji B Oncol Rep; 2017 Aug; 38(2):899-907. PubMed ID: 28627705 [TBL] [Abstract][Full Text] [Related]
8. Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma. Ou DL; Shyue SK; Lin LI; Feng ZR; Liou JY; Fan HH; Lee BS; Hsu C; Cheng AL Oncotarget; 2015 Sep; 6(29):27953-65. PubMed ID: 26172295 [TBL] [Abstract][Full Text] [Related]
9. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway. He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740 [TBL] [Abstract][Full Text] [Related]
10. Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib. Zhou SL; Zhou ZJ; Hu ZQ; Huang XW; Wang Z; Chen EB; Fan J; Cao Y; Dai Z; Zhou J Gastroenterology; 2016 Jun; 150(7):1646-1658.e17. PubMed ID: 26924089 [TBL] [Abstract][Full Text] [Related]
11. RACK1 modulates apoptosis induced by sorafenib in HCC cells by interfering with the IRE1/XBP1 axis. Zhou T; Lv X; Guo X; Ruan B; Liu D; Ding R; Gao Y; Ding J; Dou K; Chen Y Oncol Rep; 2015 Jun; 33(6):3006-14. PubMed ID: 25901709 [TBL] [Abstract][Full Text] [Related]
12. Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment. Grimm D; Lieb J; Weyer V; Vollmar J; Darstein F; Lautem A; Hoppe-Lotichius M; Koch S; Schad A; Schattenberg JM; Wörns MA; Weinmann A; Galle PR; Zimmermann T BMC Cancer; 2016 Feb; 16():94. PubMed ID: 26872727 [TBL] [Abstract][Full Text] [Related]
13. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways. Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273 [TBL] [Abstract][Full Text] [Related]
14. Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells. Firtina Karagonlar Z; Koc D; Iscan E; Erdal E; Atabey N Cancer Sci; 2016 Apr; 107(4):407-16. PubMed ID: 26790028 [TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation. Zhai B; Jiang X; He C; Zhao D; Ma L; Xu L; Jiang H; Sun X Tumour Biol; 2015 Apr; 36(4):2323-34. PubMed ID: 25416439 [TBL] [Abstract][Full Text] [Related]
16. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α. Xu H; Zhao L; Fang Q; Sun J; Zhang S; Zhan C; Liu S; Zhang Y PLoS One; 2014; 9(12):e115565. PubMed ID: 25531114 [TBL] [Abstract][Full Text] [Related]
17. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro. Qu Z; Wu J; Wu J; Luo D; Jiang C; Ding Y J Exp Clin Cancer Res; 2016 Sep; 35(1):159. PubMed ID: 27716356 [TBL] [Abstract][Full Text] [Related]
18. Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells. Ou DL; Shen YC; Yu SL; Chen KF; Yeh PY; Fan HH; Feng WC; Wang CT; Lin LI; Hsu C; Cheng AL Cancer Res; 2010 Nov; 70(22):9309-18. PubMed ID: 21062976 [TBL] [Abstract][Full Text] [Related]
19. Effects of sorafenib on lung metastasis in rats with hepatocellular carcinoma: the role of microRNAs. Shi Y; Huang A Tumour Biol; 2015 Nov; 36(11):8455-63. PubMed ID: 26026584 [TBL] [Abstract][Full Text] [Related]
20. Vascular CXCR4 Expression Promotes Vessel Sprouting and Sensitivity to Sorafenib Treatment in Hepatocellular Carcinoma. Xu J; Liang J; Meng YM; Yan J; Yu XJ; Liu CQ; Xu L; Zhuang SM; Zheng L Clin Cancer Res; 2017 Aug; 23(15):4482-4492. PubMed ID: 28223275 [No Abstract] [Full Text] [Related] [Next] [New Search]